|
|
|
|
Anti-VEGF injection improves BCVA in patients with macular edema due to BRVO
Intravitreal injection of pegaptanib treated macular edema secondary to branch retinal vein occlusion, according to a study.Intravitreal Macugen (pegaptanib sodium injection, Eyetech/Pfizer), a selective VEGF inhibitor, is approved for treatment of age...
|
|
|
Combination therapy with verteporfin and anti-VEGF agents in neovascular age-related macular degeneration: where do we stand?
Choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) is responsible for 75% of the severe vision loss attributable to AMD.1 The pathogenesis of CNV is complex, involving angiogenic and vascular components.2 3 The current...
|
|
|
Medical News: Study Published In The American Journal Of Ophthalmology Examines Investigational Use Of Macugen In Patients With Branch Retinal Vein Occlusion
Eyetech Inc.announced the results of a preliminary study assessing the investigational use of Macugen for macular edema secondary to branch retinal vein occlusion (BRVO) that were published in the January issue of the American Journal of Ophthalmology ...
|
|
|
Study Published in the American Journal of Ophthalmology Examines
PALM BEACH GARDENS, FL -- (Marketwire) -- 01/29/10 -- Eyetech Inc.announced today the results of a preliminary study assessing the investigational use of Macugen for macular edema secondary to branch retinal vein occlusion (BRVO) that were published in...
|
|
|
Study Published in the American Journal of Ophthalmology Examines Investigational Use of Macugen in Patients W
Market Wire - Jan.29, 2010 PALM BEACH GARDENS, FL -- (MARKET WIRE) -- 01/29/10 -- Eyetech Inc. announced today the results of a preliminary study assessing the investigational use of Macugen for macular edema secondary to branch retinal vein...
|
|
|
Study Published in the American Journal of Ophthalmology Examines Investigational Use of Macugen in Patients With Branch Retinal Vein Occlusion (BRVO)
Companies mentioned in this article: Eyetech Inc.PALM BEACH GARDENS, FL -- (Marketwire) -- 01/29/10 -- Eyetech Inc. announced today the results of a preliminary study assessing the investigational use of Macugen for macular edema secondary to branch...
|
|
|
Innovation Summit Highlights the Opportunities and Challenges
In late October, nearly 400 industry leaders, researchers, clinic-ians and professionals in business development and technology transfer attended the Ophthalmology Innovation Summit, held immediately prior to the :American Academy of Ophthalmology meeting in...
|
